NEW YORK (GenomeWeb) – Provista Diagnostics presented two studies at last week's San Antonio Breast Cancer Symposium as it continues development efforts for its Videssa Breast proteomic breast cancer test.

The company is also participating in the US government's Cancer Moonshot program, working within the program's Blood Profiling Atlas Project to analyze sources of pre-analytical variation in its test and those of other companies, Judy Wolf, Provista's chief medical officer, told GenomeWeb.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.